Antisense inhibition of E2A-Pbx1 expression
US6607915B1 · kind B1 · utility
1Cited by
1References
25Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 25, 2000 |
| Grant date | Aug 19, 2003 |
| Priority date | — |
| Expiry date | Jul 25, 2020 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02P20/582
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compounds, compositions and methods are provided for inhibiting E2A-Pbx1 mediated transformation. The compositions comprise antisense compounds targeted to nucleic acids encoding E2A-Pbx1. Methods of using these antisense compounds for inhibition of E2A-Pbx1 expression and for treatment of diseases, particularly cancers, associated with overexpression or constitutive activation of E2A-Pbx1 are provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.